MONTRÉAL, April 7, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that David Millette, Co-Chief Executive and Chief Operating Officer will present a corporate overview at the Locust Walk Stem Cell Tx Conference, hosted in partnership with the Harvard Stem Cell Institute, on Monday, April 11, 2022 at 10:40 a.m. ET. Mr. Millette will discuss ExCellThera’s lead technology, ECT-001, one of the company’s next generation cell therapies currently under development.
The event will be webcast live.
About ExCellThera Inc.
ExCellThera is a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera’s most advanced technology, ECT-001, a cell therapy, combines a proprietary molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its cell expansion and engineering platform, as well as supporting best-in-class clinical trials. excellthera.com
